Triodos Investment Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.7M Buy
142,000
+22,900
+19% +$4.75M 1.69% 24
2026
Q1
$26.7M Sell
119,100
-1,500
-1% -$374K 2.02% 22
2025
Q4
$29.3M Hold
120,600
2.12% 20
2025
Q3
$33M Sell
120,600
-1,100
-0.9% -$300K 2.39% 16
2025
Q2
$31.4M Sell
121,700
-12,700
-9% -$3.03M 2.36% 18
2025
Q1
$29.6M Sell
134,400
-800
-0.6% -$187K 2.43% 17
2024
Q4
$30.9M Hold
135,200
2.5% 18
2024
Q3
$33M Buy
135,200
+3,400
+3% +$760K 2.6% 15
2024
Q2
$25.2M Buy
131,800
+17,300
+15% +$3.51M 2.2% 20
2024
Q1
$22.7M Buy
+114,500
New +$21M 2.05% 26
2021
Q1
Sell
-15,000
Closed -$3.19M 36
2020
Q4
$3.19M Hold
15,000
0.53% 35
2020
Q3
$2.57M Hold
15,000
0.53% 33
2020
Q2
$2.88M Hold
15,000
0.68% 34
2020
Q1
$2.21M Sell
15,000
-2,000
-12% -$319K 0.62% 33
2019
Q4
$2.63M Buy
17,000
+2,000
+13% +$288K 0.59% 35
2019
Q3
$2.03M Sell
15,000
-5,000
-25% -$655K 0.51% 35
2019
Q2
$2.44M Sell
20,000
-40,000
-67% -$4.43M 0.56% 36
2019
Q1
$6.24M Hold
60,000
1.26% 26
2018
Q4
$6.83M Sell
60,000
-12,000
-17% -$1.29M 1.47% 24
2018
Q3
$8.3M Hold
72,000
1.44% 26
2018
Q2
$7.46M Buy
+72,000
New +$7.29M 1.4% 30

Other funds holding RMD

Triodos Investment Management's RMD Position: Q2 2026 in Review

Triodos Investment Management increased its ResMed (RMD) stake by 19% in Q2 2026, buying an estimated $4.75M and bringing the position to 142,000 shares worth $27.7M. The position accounts for 1.69% of the portfolio, ranked #24.

Triodos Investment Management first reported a position in RMD in Q2 2018 and has held it in 21 quarters since. The position peaked at $33M in Q3 2025. 319 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Triodos Investment Management held 142,000 shares of ResMed worth $27.7M as of Q2 2026.
  • Triodos Investment Management bought 22,900 ResMed shares in Q2 2026, an estimated $4.75M.
  • ResMed made up 1.69% of Triodos Investment Management's portfolio in Q2 2026, its #24 holding.
  • Triodos Investment Management first reported a position in ResMed in Q2 2018 and has held it in 21 quarters since.
  • Triodos Investment Management's ResMed position peaked at $33M in Q3 2025.
  • 319 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Triodos Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.